Thermo Fisher Scientific (TMO): financials, SEC filings and peers
Thermo Fisher Scientific (TMO) is a life sciences tools & services company in the Health Care sector of the S&P 500, headquartered in Waltham, Massachusetts.
It was founded in 2006 and joined the S&P 500 on August 3, 2004.
Its fiscal year ends in December, and its shares trade on the NYSE.
In its SEC filings it is classified as “Measuring & Controlling Devices, NEC”.
Thermo Fisher Scientific at a glance
- Revenue (12 months)
- $46.3B
- Revenue growth
- +7.2%
- Operating margin
- 17.6%
- Net income (12 months)
- $7.0B
- Free cash flow (12 months)
- $7.3B
- Cash
- $4.1B
- Debt
- $42.3B
- Diluted EPS (12 months)
- $18.59
Twelve months to June 27, 2026, from the 10-Q filed July 31, 2026.
Latest twelve months
Over the twelve months to June 27, 2026, Thermo Fisher Scientific reported revenue of $46.3 billion, about the same as a year earlier (+7.2%).
Its operating margin was 17.6%: for every $100 of sales, about $18 was left as operating profit.
Net income was $7.0 billion (15.0% of revenue), 5.8% higher than a year earlier.
Operating cash flow was $9.0 billion and capital spending $1.7 billion, leaving free cash flow of $7.3 billion (15.8% of revenue).
At the end of the period it held $4.1 billion in cash and $42.3 billion in debt, a net debt position of $38.2 billion.
The diluted share count fell 1.9% in a year, typically the result of buybacks.
Five-year trend
- Revenue went from $32.2 billion in fiscal 2020 to $44.6 billion in fiscal 2025, about 6.7% a year.
- Operating margin narrowed from 24.2% to 17.4% over the same years.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $39.2B | $44.9B | $42.9B | $42.9B | $44.6B |
| Revenue growth | 21.7% | 14.5% | -4.6% | 0.1% | 3.9% |
| Operating margin | 25.6% | 18.7% | 16.0% | 17.1% | 17.4% |
| Net income | $7.7B | $7.0B | $6.0B | $6.3B | $6.7B |
| Free cash flow | $6.8B | $6.9B | $6.9B | $7.3B | $6.3B |
| Diluted EPS | $19.46 | $17.63 | $15.45 | $16.53 | $17.74 |
Fiscal years as reported in Thermo Fisher Scientific’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
Companies like Thermo Fisher Scientific
Other S&P 500 companies in Life Sciences Tools & Services:
- AAgilent TechnologiesSanta Clara, California
- CRLCharles River LaboratoriesWilmington, Massachusetts
- DHRDanaher CorporationWashington, D.C.
- ILMNIllumina, Inc.San Diego, California
- IQVIQVIADurham, North Carolina
- MTDMettler ToledoColumbus, Ohio
- TECHBio-TechneMinneapolis, Minnesota
- WATWaters CorporationMilford, Massachusetts
More from Health Care
Questions about Thermo Fisher Scientific
Is Thermo Fisher Scientific's revenue growing?
Yes. Revenue for the twelve months to June 27, 2026 was $46.3 billion, up 7.2% from a year earlier, according to its SEC filings.
Is Thermo Fisher Scientific profitable?
Yes. It earned $7.0 billion in net income over the twelve months to June 27, 2026, a net margin of 15.0%.
Does Thermo Fisher Scientific have more cash or more debt?
At June 27, 2026 it had $4.1 billion in cash and $42.3 billion in debt, so more debt than cash.
When did Thermo Fisher Scientific last file financial results?
Its latest quarterly report (10-Q) was filed with the SEC on July 31, 2026.
Which companies are similar to Thermo Fisher Scientific?
In the S&P 500, Thermo Fisher Scientific is grouped in Life Sciences Tools & Services within the Health Care sector. Agilent Technologies (A), Charles River Laboratories (CRL), Danaher Corporation (DHR), Illumina, Inc. (ILMN), IQVIA (IQV) are in the same group.
Understand the numbers
Source: Thermo Fisher Scientific’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.